A precision T-cell therapy stalls treatment-resistant cancers in clinical trial
Marengo Therapeutics' Invikafusp alfa shows promise in treating TMB-H solid tumors resistant to standard immune checkpoint blockade.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
A precision T-cell therapy called invikafusp alfa demonstrated activity in TMB-H solid tumors during the Phase 1/2 START-001 trial. Results presented at ESMO 2026 showed the bispecific antibody shrunk eight tumor types in Phase 2.
The immunotherapy drug generated promising results for cancers mostly unresponsive to immune checkpoint blockade.
Epilogue added 20d ago, after coverage quieted.
The brief
A novel precision T-cell therapy called invikafusp alfa has demonstrated the ability to stall treatment-resistant cancers during a clinical trial. Developed by Marengo Therapeutics, this bispecific dual T-cell agonist was tested as part of the Phase 1/2 START-001 trial. The drug has shown tissue-agnostic single-agent activity specifically in solid tumors characterized by high tumor mutational burden (TMB-H). These tumors are noted for being mostly unresponsive to traditional immune checkpoint blockade. Results indicate that the therapy successfully shrunk tumors across eight different tumor types during its Phase 2 testing stage. Coverage of these developments has been widespread across scientific and mainstream outlets.
Nature provided a detailed look at the Phase 1/2 START-001 trial, while AOL.com specifically highlighted the drug's efficacy in TMB-H solid tumors. Medical Xpress focused on the therapy's ability to stall resistant cancers, and BioSpace emphasized the shrinking of eight tumor types. Additionally, Mass General Brigham reported that the immunotherapy drug generated promising clinical trial results, and the Toronto Star shared a personal account of a patient who viewed the early-stage Toronto treatment as a lifesaver after doctors had given him only two or three months to live. This development is significant because it targets a specific patient population—those with TMB-H solid tumors—who typically do not respond to current immune checkpoint blockade treatments. The nature of invikafusp alfa as a bispecific antibody allows it to act as a dual T-cell agonist, providing a different mechanism for immunotherapy. The transition from Phase 1 to Phase 2 testing suggests a progression in the drug's clinical validation.
By demonstrating tissue-agnostic activity, the treatment suggests it may work regardless of where the tumor is located in the body, provided the TMB-H marker is present. Future developments will center on the findings presented at ESMO 2026. Observers will be monitoring the continued results of the START-001 trial to see if the activity seen in the eight tumor types remains consistent. Coverage does not yet specify the long-term survival rates or the full range of side effects associated with invikafusp alfa. The focus remains on the drug's potential as a single-agent therapy for those who have failed other immunotherapy options. Further updates from Marengo Therapeutics regarding the expansion of these trials are expected following the ESMO 2026 presentations.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 21d ago.
Quick answers
What is the name of the drug used in the trial?
The drug is called invikafusp alfa, developed by Marengo Therapeutics.
Which specific types of tumors did the therapy target?
The therapy targeted TMB-H (high tumor mutational burden) solid tumors that were mostly unresponsive to immune checkpoint blockade.
Where were the Phase 2 results presented?
The results of the STARt-001 trial were presented at ESMO 2026.
Coverage (6)
- His doctors gave him 2 or 3 months. A new early-stage Toronto cancer treatment has been a ‘lifesaver’ Toronto Star · 25d ago
- ESMO 2026: Marengo’s bispecific antibody shrinks 8 tumor types in Phase 2 BioSpace · 25d ago
- Novel cancer immunotherapy drug generates promising clinical trial results Mass General Brigham · 25d ago
- Marengo Therapeutics Presents Phase 2 STARt-001 Results at ESMO 2026 Demonstrating Tissue-Agnostic Single-Agent Activity of Invikafusp Alfa in TMB-H Solid Tumors Mostly Unresponsive to Immune Checkpoint Blockade AOL.com · 25d ago
- Bispecific dual T cell agonist invikafusp alfa in solid tumors: the phase 1/2 START-001 trial Nature · 25d ago
- A precision T-cell therapy stalls treatment-resistant cancers in clinical trial Medical Xpress · 25d ago
Topics
Related trends
Experimental drug eliminates 75% of aggressive pancreatic tumors and enhances immune system memory
MedPacto reported that its experimental drug MP010 eliminated 75% to 87.5% of aggressive pancreatic tumors in mice.
Why the simple flu shot could be a surprise weapon against cancer
Research suggests seasonal influenza vaccines may activate immune responses against skin cancer tumors in early studies.
Incyte pancreatic cancer medicine induces lasting tumor responses, company says at ESMO
Incyte presents new early clinical data at ESMO for its KRAS G12D-targeted pancreatic and colorectal cancer medicine.
Cancer Vaccines Are the N.I.H.’s Next ‘Big Bet’
Cancer vaccines emerge as a major focus for the N.I.H. through a newly announced public-private partnership.
High-fat diet activates cellular repair pathway that helps colon cancer spread
Recent scientific studies reveal how high-fat diets and tumor metabolism can help colorectal cancer spread to the liver.
Cancer-fighting T cells need small amounts of ROS to attack tumors, study finds - News-Medical
New research reveals that tumors may weaponize antioxidant proteins to disable the reactive oxygen species T cells need to destroy cancer.